|
|
News Breaks
|
October 14, 2009
|
| 08:47 EDT |  | NEXM |
| theflyonthewall.com: | NexMed to pursue signing partner for anti-fungal product | | NexMed announced that it has completed its post hoc analysis of NM100060, the Company’s topically-applied treatment for onychomycosis, commonly known as nail fungus. Based on this analysis, NexMed seeks to pursue signing a partner for further development of the product. NM100060 has previously been tested in approximately 2,000 patients enrolled in three Phase 3 clinical studies conducted by Novartis. On July 7, 2009, the Company announced the mutual decision with Novartis to terminate the exclusive, global licensing agreement for NM100060. :theflyonthewall.com |
|
|
News For NEXM From The Last 14 Days Check below for free stories on NEXM the last two weeks.
| Sign up for a free trial to see the rest of the stories you've been missing. |
There are no results for these search parameters.
|
|
|
|
